|Bid||1.100 x 1300|
|Ask||1.120 x 4000|
|Day's Range||1.060 - 1.120|
|52 Week Range||0.880 - 3.090|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.00|
If you own shares in Neuralstem Inc (NASDAQ:CUR) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure ofRead More...
-Phase 2 clinical trial initiated to further evaluate NSI-566 as treatment for ischemic stroke-- NSI-189 Granted Orphan Drug Designation for the Treatment of Angelman Syndrome-- Jim Scully appointed interim ...
Neuralstem, Inc. (CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to NSI-189 for the treatment of Angelman syndrome. “Angelman Syndrome is a rare disease with significant unmet medical need, and for which there are no FDA-approved therapies,” said Jim Scully, Chief Executive Officer of Neuralstem.
Key story highlights: Germantown biopharmaceutical company Neuralstem Inc. named Jim Scully interim CEO. The board also appointed William Oldaker, a member of the board since 2007, as chairman. Maryland stem cell therapy company Neuralstem Inc. (NASDAQ: CUR) has named Jim Scully interim CEO.
Neuralstem, Inc. (CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule compound technologies, today announced that the Board of Directors has appointed Jim Scully as interim chief executive officer.
GERMANTOWN, Md., Aug. 01, 2018-- In a release issued yesterday by Neuralstem, Inc., please note the headline should be, "Neuralstem Announces Initiation of Phase 2 Clinical Trial of NSI-566 in Ischemic ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 31) Allakos Inc (NASDAQ: ALLK ) (listed July 19 following its IPO) ...
Neuralstem, Inc. (CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, today announced the initiation of a Phase 2 clinical trial evaluating NSI-566, the Company’s lead neural stem cell candidate, as a potential treatment for ischemic stroke. Neuralstem announced the positive topline results of Phase 1 stroke study in the 2018 ISSCR (International Society for Stem Cell Research) abstract on June 23, 2018.
Neuralstem, Inc. (CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced the presentation of data at the Alzheimer's Association International Conference in Chicago, Illinois, demonstrating that oral administration of NSI-189 in a mouse model of Alzheimer’s Disease leads to a significant amelioration and/or improvement in cognition measures and anxiety.
Stock Monitor: Neuralstem Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 18, 2018 / Active-Investors.com has just released a free research report on Idera Pharma, Inc. (NASDAQ: IDRA ) ("Idera"). ...
NEW YORK, NY / ACCESSWIRE / April 11, 2018 / U.S. equities regained their footing on Tuesday, as trade tensions between the U.S. and China calmed after comments from the Chinese President Xi Jinping. The ...